Who
Timothy E. Morris
Director
Company insider
Files Form 4 as: Director, Aquestive Therapeutics; Director, DBV Technologies; COO and CFO, Humanigen; Chief Financial Officer, Iovance Biotherapeutics; Chief Financial Officer, Talphera; VP, Finance and CFO, Vivus.
In numbers
- Trades disclosed
- 75
- Buys
- 1
- Sells
- 6
- Bought
- $18K
- Sold
- $8.2M
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 30 Jan 2006
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $143K42,000 at $3.41 | filing |
| 20 Jun 2024filed 21 Jun 2024 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 25 Aug 2023filed 28 Aug 2023 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Bought | $18K12,000 at $1.52 | filing |
| 21 Jun 2023filed 23 Jun 2023 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 16 Aug 2022filed 17 Aug 2022 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —28,500 at $0.00 | filing |
| 27 Jul 2022filed 29 Jul 2022 | Humanigenoption or derivative | SEC FORM 4 Code A | —600,360 at $0.00 | filing |
| 12 Jan 2022filed 14 Jan 2022 | Humanigenoption or derivative | SEC FORM 4 Code A | —59,841 at $0.00 | filing |
| 31 Dec 2021filed 4 Jan 2022 | Humanigenoption or derivative | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 10 Jun 2021filed 11 Jun 2021 | DBVT DBV Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code P | $49K6,837 at $7.12 | filing |
| 18 Sep 2020filed 22 Sep 2020 | Humanigenoption or derivative | SEC FORM 4 Code A | —151,316 at $0.00 | filing |
| 4 Mar 2019filed 6 Mar 2019 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 9 Mar 2018filed 13 Mar 2018 | Humanigenoption or derivative | SEC FORM 4 Code A | —715,877 at $0.00 | filing |
| 9 Mar 2018filed 13 Mar 2018 | Humanigenoption or derivative | SEC FORM 4 Code A | —88,235 at $0.00 | filing |
| 14 Aug 2017filed 16 Aug 2017 | IOVA Iovance Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 7 Feb 2017filed 9 Feb 2017 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 13 Sep 2016filed 15 Sep 2016 | Kalobios Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 10 Feb 2016filed 18 Feb 2016 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,500 at $0.00 | filing |
| 29 Apr 2015filed 1 May 2015 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)DBVT · dailypolitical.com · 21 Oct 2026DBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low – What's Next?DBVT · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Timothy E. Morris; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.